Literature DB >> 11971105

Quantitative functional measures in MS: what is a reliable change?

S R Schwid1, A D Goodman, M P McDermott, C F Bever, S D Cook.   

Abstract

As a first step toward understanding which changes should be considered as meaningful, the authors assessed the reliability of quantitative functional tests on 5 consecutive days in 63 patients with MS, determining the range of measurement variability present when patients are clinically stable. Time to walk 25 feet (T25FW) and the 9-hole peg test (9HPT) varied by <20% of individual mean scores on repeated testing. Therefore, a 20% change on these tests can be considered to be the threshold that reliably indicates a true change in function for an individual.

Entities:  

Mesh:

Year:  2002        PMID: 11971105     DOI: 10.1212/wnl.58.8.1294

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Estimates of the walking distance in multiple sclerosis patients and their effect on the EDSS.

Authors:  Isabel Ringel; U K Zettl
Journal:  J Neurol       Date:  2006-04-20       Impact factor: 4.849

2.  New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.

Authors:  Tim Sinnecker; Esther Ruberte; Sabine Schädelin; Vera Canova; Michael Amann; Yvonne Naegelin; Iris-Katharina Penner; Jannis Müller; Jens Kuhle; Bernhard Décard; Tobias Derfuss; Ludwig Kappos; Cristina Granziera; Jens Wuerfel; Stefano Magon; Özgür Yaldizli
Journal:  J Neurol       Date:  2019-10-14       Impact factor: 4.849

3.  Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Authors:  Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

4.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

5.  Psychometric properties of measures of upper limb activity performance in adults with and without spasticity undergoing neurorehabilitation-A systematic review.

Authors:  Shannon Pike; Anne Cusick; Kylie Wales; Lisa Cameron; Lynne Turner-Stokes; Stephen Ashford; Natasha A Lannin
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

6.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 7.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

8.  A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.

Authors:  Andrew D Goodman; Theodore R Brown; Randall T Schapiro; Michael Klingler; Ron Cohen; Andrew R Blight
Journal:  Int J MS Care       Date:  2014

9.  Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.

Authors:  Ruggero Capra; Vincenzo Brescia Morra; Massimiliano Mirabella; Claudio Gasperini; Cinzia Scandellari; Rocco Totaro; Nicola De Rossi; Silvia Masera; Valentina Zipoli; Francesco Patti
Journal:  Neurol Sci       Date:  2020-11-17       Impact factor: 3.307

10.  Adaptive robot training for the treatment of incoordination in Multiple Sclerosis.

Authors:  Elena Vergaro; Valentina Squeri; Giampaolo Brichetto; Maura Casadio; Pietro Morasso; Claudio Solaro; Vittorio Sanguineti
Journal:  J Neuroeng Rehabil       Date:  2010-07-29       Impact factor: 4.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.